5-Ethynyluridine: A Nucleoside Analog with Bioorthogonal Labeling Potential for mRNA Therapeutics

I. Expression Characteristics and Mechanism Analysis of EU-Modified mRNA

To evaluate the impact of EU modification on mRNA function, researchers synthesized yellow fluorescent protein (YFP)-encoding mRNAs with all uridines replaced by EU, Ψ, m1Ψ, or unmodified uridine (U). After electroporation transfection into human macrophages, flow cytometry revealed that EU-modified mRNA exhibited significantly lower YFP protein expression levels compared to other groups (m1Ψ > U > Ψ > EU). However, the expression levels remained stable over the observation period, indicating that EU modification did not lead to rapid degradation of protein products.

Further mechanistic investigations revealed multiple factors contributing to the expression differences. First, quantitative PCR analysis showed that the intracellular abundance of EU-modified mRNA was approximately one-tenth of other modified forms, suggesting potential differences in transfection or intracellular stability. Second, results from a cell-free in vitro translation system ruled out interference from cell-specific factors, confirming that EU-modified mRNA itself had the lowest translation efficiency (about 1/10 of unmodified mRNA). Collectively, these findings indicate that the lower protein yield of EU-modified mRNA results from the combined effects of transfection/stability and inherent translation efficiency.

II. Low Immunogenicity of EU-Modified mRNA

Assessing the immunostimulatory potential of nucleoside analogs is critical. The study evaluated innate immune responses by measuring key inflammatory cytokines and interferon-stimulated gene expression. Enzyme-linked immunosorbent assays (ELISA) showed that 24 hours post-transfection, all modified mRNAs (EU, Ψ, m1Ψ) induced low levels of interleukin-6 (IL-6), with the EU-modified group showing statistically significant differences compared to the unmodified U group, demonstrating its effective immune-silencing capability.

Transcriptional analysis of downstream interferon pathway gene MX1 and immune-related genes PKR and TAP2 further confirmed this observation. Unmodified and Ψ-modified mRNAs induced some upregulation of MX1 expression, whereas EU and m1Ψ-modified mRNAs showed no significant changes. For PKR and TAP2, EU and m1Ψ modifications also displayed no activation effects and even slight suppression. These data consistently indicate that EU modification, like m1Ψ, effectively avoids triggering innate immune recognition pathways by mRNA.

III. Impact of EU Modification on mRNA Secondary Structure

To investigate whether the observed phenotypes stem from altered mRNA folding, the study employed SHAPE-MaP technology to analyze the secondary structures of differently modified mRNAs. Results showed that Ψ and m1Ψ-modified mRNAs had highly similar structures, which differed significantly from unmodified U mRNA. In contrast, EU-modified mRNA exhibited global folding closest to unmodified U mRNA. In-depth analysis revealed that Ψ and m1Ψ likely influence structure by enhancing base-pairing stability, whereas EU has a relatively weaker impact on base pairing, with reactivity profiles differing from natural uridine but distinct from Ψ/m1Ψ. This suggests that while EU, Ψ, and m1Ψ all alter the local chemical environment, they induce different structural consequences, with EU's phenotype largely independent of reshaping the overall folding of natural mRNA.

IV. Conclusions and Future Perspectives

This study systematically characterizes the properties of 5-ethynyluridine (EU) as a uridine substitute in mRNA. Key findings include:

1. Low Immunogenicity: EU modification effectively prevents innate immune activation in macrophages, with efficacy comparable to the widely used m1Ψ.
2. Unique Expression and Folding Properties: EU modification reduces mRNA transfection/stability and translation efficiency but maintains stable protein expression. Its modified mRNA secondary structure more closely resembles the natural form, distinct from Ψ/m1Ψ.
3. Bioorthogonal Labeling Potential: The alkyne group in EU is a key advantage, enabling specific mRNA labeling and tracking via click chemistry, which holds significant value for imaging, localization, or affinity purification applications.

In summary, 5-ethynyluridine is not only an effective immune-silencing modification but also, due to its unique chemical and structural properties—particularly the chemical handle it provides for bioorthogonal labeling—holds broad prospects for basic research and the refined development of next-generation mRNA therapeutics and vaccines.

V. Which Manufacturers Provide EU Labeling Products?

Nanjing U-Protein自主研发的 Protein labeling EU (5-ethynyluridine) (Product No.: UA086024) is a high-efficiency, specific protein labeling tool developed based on 5-ethynyluridine (EU) click chemistry labeling technology. This product utilizes EU as a uridine analog, which can be incorporated into nascent RNA strands during RNA synthesis and then efficiently conjugated with fluorescent dyes or biotin reporters via click chemistry, enabling RNA labeling and visualization. It is suitable for RNA transcription and metabolic tracking, cell proliferation assays, imaging analysis, and high-throughput screening.

Nanjing U-Protein is committed to providing innovative and efficient labeling and detection tools for cell biology, transcriptomics, and drug development. For detailed technical information, protocols, or application support regarding Protein labeling EU (5-ethynyluridine) (Product No.: UA086024), please feel free to contact us.